14th International Congress on Myeloproliferative Neoplasms
The 14th International Congress on Myeloproliferative Neoplasms (MPNs), held October 27-28 in Brooklyn, New York, featured a range of topics, including the latest in clinical trials, transcriptional profiling of extracellular matrix-related genes in MPNs, and more.
Advertisement
A large analysis of real-world treatment outcomes in patients with myelofibrosis who were treated with ruxolitinib.
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol.
As TKIs have become available to patients, survival for those with CML has significantly improved but disparities.
VERIFY, a phase III trial of the hepcidin mimetic rusfertide (PTG-300), is now enrolling patients with PV.
IFN alpha-2 influences the regulation of several ECM genes involved in tissue remodeling.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.